Clovis Oncology, Pfizer, and GlaxoSmithKline have also marketed rival PARP drugs, with the latter ... have claimed FDA approval for a second antibody-drug conjugate for breast cancer - TROP2 ...

Patrys’s technology brings together all the advantages of antibodies—including specificity and safety—with those of DDR therapies, such as PARP inhibitors, that target DDR deficiencies ...

Cite this: SABCS 2024: New Treatment Options in HR+/HER2- Breast Cancer - Medscape - Jan 10, 2025.

Novotech, the leading global full-service clinical Contract Research Organization (CRO), has released a comprehensive report analyzing the global clinical trial and drug development landscape for ...